152 related articles for article (PubMed ID: 33809034)
1. 3-Hydroxypropane-1,2-Diyl Dipalmitoleate-A Natural Compound with Dual Roles (CB1 Agonist/FAAH1 Blocker) in Inhibiting Ovarian Cancer Cell Line.
Sathynathan CV; Raman LS; Vajiravelu S; Kumar TD; Panchatcharam TS; Narasimhan G; Doss GCP; Krishnan MEG
Pharmaceuticals (Basel); 2021 Mar; 14(3):. PubMed ID: 33809034
[TBL] [Abstract][Full Text] [Related]
2. A Novel Non-Psychoactive Fatty Acid from a Marine Snail,
Vijayaraghavan CS; Raman LS; Surenderan S; Kaur H; Chinambedu MD; Thyagarajan SP; Gnanambal Krishnan ME
Molecules; 2024 Apr; 29(8):. PubMed ID: 38675558
[TBL] [Abstract][Full Text] [Related]
3. Cisplatin-induced ototoxicity involves interaction of PRMT3 and cannabinoid system.
Lim JO; Ko JW; Shin NR; Jung TY; Moon C; Kim HC; Shin IS; Kim JC
Arch Toxicol; 2019 Aug; 93(8):2335-2346. PubMed ID: 31256211
[TBL] [Abstract][Full Text] [Related]
4. The bioactive conformation of aminoalkylindoles at the cannabinoid CB1 and CB2 receptors: insights gained from (E)- and (Z)-naphthylidene indenes.
Reggio PH; Basu-Dutt S; Barnett-Norris J; Castro MT; Hurst DP; Seltzman HH; Roche MJ; Gilliam AF; Thomas BF; Stevenson LA; Pertwee RG; Abood ME
J Med Chem; 1998 Dec; 41(26):5177-87. PubMed ID: 9857088
[TBL] [Abstract][Full Text] [Related]
5. Structure-Based Identification of Potent Natural Product Chemotypes as Cannabinoid Receptor 1 Inverse Agonists.
Pandey P; Roy KK; Liu H; Ma G; Pettaway S; Alsharif WF; Gadepalli RS; Rimoldi JM; McCurdy CR; Cutler SJ; Doerksen RJ
Molecules; 2018 Oct; 23(10):. PubMed ID: 30322136
[TBL] [Abstract][Full Text] [Related]
6. Synthetic cannabinoid receptor agonists: classification and nomenclature.
Potts AJ; Cano C; Thomas SHL; Hill SL
Clin Toxicol (Phila); 2020 Feb; 58(2):82-98. PubMed ID: 31524007
[No Abstract] [Full Text] [Related]
7. Design, synthesis, and binding studies of new potent ligands of cannabinoid receptors.
Brizzi A; Brizzi V; Cascio MG; Bisogno T; Sirianni R; Di Marzo V
J Med Chem; 2005 Nov; 48(23):7343-50. PubMed ID: 16279794
[TBL] [Abstract][Full Text] [Related]
8. Anticonvulsant effect of cannabinoid receptor agonists in models of seizures in developing rats.
Huizenga MN; Wicker E; Beck VC; Forcelli PA
Epilepsia; 2017 Sep; 58(9):1593-1602. PubMed ID: 28691158
[TBL] [Abstract][Full Text] [Related]
9. Expression and distribution of key proteins of the endocannabinoid system in the human seminal vesicles.
Ückert S; la Croce G; Bettiga A; Albrecht K; Buono R; Benigni F; Kuczyk MA; Hedlund P
Andrologia; 2018 Mar; 50(2):. PubMed ID: 28786134
[TBL] [Abstract][Full Text] [Related]
10. Mead ethanolamide, a novel eicosanoid, is an agonist for the central (CB1) and peripheral (CB2) cannabinoid receptors.
Priller J; Briley EM; Mansouri J; Devane WA; Mackie K; Felder CC
Mol Pharmacol; 1995 Aug; 48(2):288-92. PubMed ID: 7651362
[TBL] [Abstract][Full Text] [Related]
11. Involvement of the CB
Khan MI; Sobocińska AA; Brodaczewska KK; Zielniok K; Gajewska M; Kieda C; Czarnecka AM; Szczylik C
BMC Cancer; 2018 May; 18(1):583. PubMed ID: 29792186
[TBL] [Abstract][Full Text] [Related]
12. Arachidonylsulfonyl derivatives as cannabinoid CB1 receptor and fatty acid amide hydrolase inhibitors.
Segall Y; Quistad GB; Nomura DK; Casida JE
Bioorg Med Chem Lett; 2003 Oct; 13(19):3301-3. PubMed ID: 12951114
[TBL] [Abstract][Full Text] [Related]
13. Cannabinoid receptor activation induces apoptosis through tumor necrosis factor alpha-mediated ceramide de novo synthesis in colon cancer cells.
Cianchi F; Papucci L; Schiavone N; Lulli M; Magnelli L; Vinci MC; Messerini L; Manera C; Ronconi E; Romagnani P; Donnini M; Perigli G; Trallori G; Tanganelli E; Capaccioli S; Masini E
Clin Cancer Res; 2008 Dec; 14(23):7691-700. PubMed ID: 19047095
[TBL] [Abstract][Full Text] [Related]
14. Anticonvulsant effects of N-arachidonoyl-serotonin, a dual fatty acid amide hydrolase enzyme and transient receptor potential vanilloid type-1 (TRPV1) channel blocker, on experimental seizures: the roles of cannabinoid CB1 receptors and TRPV1 channels.
Vilela LR; Medeiros DC; de Oliveira AC; Moraes MF; Moreira FA
Basic Clin Pharmacol Toxicol; 2014 Oct; 115(4):330-4. PubMed ID: 24674273
[TBL] [Abstract][Full Text] [Related]
15. Effects of endocannabinoid 1 and 2 (CB1; CB2) receptor agonists on luteal weight, circulating progesterone, luteal mRNA for luteinizing hormone (LH) receptors, and luteal unoccupied and occupied receptors for LH in vivo in ewes.
Tsutahara NM; Weems YS; Arreguin-Arevalo JA; Nett TM; LaPorte ME; Uchida J; Pang J; McBride T; Randel RD; Weems CW
Prostaglandins Other Lipid Mediat; 2011 Feb; 94(1-2):17-24. PubMed ID: 21109016
[TBL] [Abstract][Full Text] [Related]
16. Cannabinoid CB1 and CB2 receptors and fatty acid amide hydrolase are specific markers of plaque cell subtypes in human multiple sclerosis.
Benito C; Romero JP; Tolón RM; Clemente D; Docagne F; Hillard CJ; Guaza C; Romero J
J Neurosci; 2007 Feb; 27(9):2396-402. PubMed ID: 17329437
[TBL] [Abstract][Full Text] [Related]
17. Elevation of endocannabinoid levels in the ventrolateral periaqueductal grey through inhibition of fatty acid amide hydrolase affects descending nociceptive pathways via both cannabinoid receptor type 1 and transient receptor potential vanilloid type-1 receptors.
Maione S; Bisogno T; de Novellis V; Palazzo E; Cristino L; Valenti M; Petrosino S; Guglielmotti V; Rossi F; Di Marzo V
J Pharmacol Exp Ther; 2006 Mar; 316(3):969-82. PubMed ID: 16284279
[TBL] [Abstract][Full Text] [Related]
18. Dysregulation of cannabinoid CB1 receptor and associated signaling networks in brains of cocaine addicts and cocaine-treated rodents.
Álvaro-Bartolomé M; García-Sevilla JA
Neuroscience; 2013 Sep; 247():294-308. PubMed ID: 23727505
[TBL] [Abstract][Full Text] [Related]
19. Biarylpyrazole inverse agonists at the cannabinoid CB1 receptor: importance of the C-3 carboxamide oxygen/lysine3.28(192) interaction.
Hurst D; Umejiego U; Lynch D; Seltzman H; Hyatt S; Roche M; McAllister S; Fleischer D; Kapur A; Abood M; Shi S; Jones J; Lewis D; Reggio P
J Med Chem; 2006 Oct; 49(20):5969-87. PubMed ID: 17004712
[TBL] [Abstract][Full Text] [Related]
20. Brain permeant and impermeant inhibitors of fatty-acid amide hydrolase suppress the development and maintenance of paclitaxel-induced neuropathic pain without producing tolerance or physical dependence in vivo and synergize with paclitaxel to reduce tumor cell line viability in vitro.
Slivicki RA; Xu Z; Mali SS; Hohmann AG
Pharmacol Res; 2019 Apr; 142():267-282. PubMed ID: 30739035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
